High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need.
Conventional thinking in modern drug discovery postulates that the design of highly selective molecules which act on a single disease-associated target will yield safer and more effective drugs. However, high clinical attrition rates and the lack of progress in developing new effective treatments for many important diseases of unmet therapeutic need challenge this hypothesis. This assumption also impinges upon the efficiency of target agnostic phenotypic drug discovery strategies, where early target deconvolution is seen as a critical step to progress phenotypic hits. In this review we provide an overview of how emerging phenotypic and pathway-profiling technologies integrate to deconvolute the mechanism-of-action of phenotypic hits. We propose that such in-depth mechanistic profiling may support more efficient phenotypic drug discovery strategies that are designed to more appropriately address complex heterogeneous diseases of unmet need.
['Hughes|Rebecca E|RE|', 'Elliott|Richard J R|RJR|', 'Dawson|John C|JC|', 'Carragher|Neil O|NO|']
D004194:Disease D055808:Drug Discovery D006801:Humans D004364:Pharmaceutical Preparations D010641:Phenotype
esophageal cancer glioblastoma high-content imaging machine learning network pharmacology structural similarity